慢性肾脏病患者的内源性维生素 D 缺乏：从实验证据到临床实践。
Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice.
机构信息
Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy.
出版信息
Nutrients. 2019 Aug 15;11(8):1918. doi: 10.3390/nu11081918.
Native hypovitaminosis D (n-hVITD) is frequently found from the early stages of chronic kidney disease (CKD) and its prevalence increases with CKD progression. Even if the implications of n-hVITD in chronic kidney disease-mineral bone disorder (CKD-MBD) have been extensively characterized in the literature, there is a lot of debate nowadays about the so called "unconventional effects" of native vitamin D (25(OH)VitD) supplementation in CKD patients. In this review, highlights of the dimension of the problem of n-hVITD in CKD stages 2-5 ND patients will be presented. In addition, it will focus on the "unconventional effects" of 25(OH)VitD supplementation, the clinical impact of n-hVITD and the most significant interventional studies regarding 25(OH)VitD supplementation in CKD stages 2-5 ND.
原发性维生素 D 缺乏症（n-hVITD）在慢性肾脏病（CKD）的早期阶段经常被发现，其患病率随着 CKD 的进展而增加。尽管 n-hVITD 在慢性肾脏病-矿物质骨异常（CKD-MBD）中的意义在文献中已经得到广泛描述，但目前对于 CKD 患者中天然维生素 D（25（OH）VitD）补充的所谓“非常规作用”仍存在很多争议。在这篇综述中，将介绍 2-5 期非透析 CKD 患者中 n-hVITD 问题的重要方面。此外，还将重点介绍 25（OH）VitD 补充的“非常规作用”、n-hVITD 的临床影响以及关于 2-5 期非透析 CKD 患者中 25（OH）VitD 补充的最有意义的干预性研究。
Zotero 插件